Re:AlphaFold-Powered Drug Discovery of a Novel CDK20 Inhibitor
by bayesian_horse on Wednesday January 26, 2022 @03:21AM
(#30083084)
The point of AlphaFold not being able to predict the impact of small changes is probably more about having only seen the "right" way those protein sequences usually look. Many point mutations will result in a fitness reduction and therefore the difference would not make it into the training set.
Re:AlphaFold-Powered Drug Discovery of a Novel CDK20 Inhibitor
by dekhn on Wednesday January 26, 2022 @11:19AM
(#30087405)
No, this is absolutely not true. For example scientists have made hundreds of point mutations and probed them, even if the "fitness" was lower (not clear what that even means in this context).
Don't forget that you can replace the three residues in the serine protease catalytic triad and still see significant proteolytic activity. Everything we know about protein activity is wrong.
Fortunately, evolution already encoded robustness against this sort of problem into proteins and the vast majority of single point mutations are tolerated (the resulting enzymes are often nearly as active and stable as the originals).